| CMS Caregiver Workgroup |
Committee, Work group, Advisory group, or Task Force |
CMS, ACL, CDC, HRSA |
NIA |
Cross-section of organizations such as caregiver organizations, aging network organizations, federal agencies, disease specific organizations, employers and CMS. |
| CMS-Medicare Current Beneficiary Survey - Dietary Supplements, Measures of Malnutrition and Frailty |
Health Survey |
CMS |
OD/DPCPSI/ODS |
The National Institutes of Health's, Office of Dietary Supplements works with the Centers of Medicare and Medicaid Service to collect data on dietary supplement use, malnutrition and measures of frailty in the Medicare Current Beneficiary Study (MCBS). MCBS is a continuous, in-person, longitudinal survey of a representative national sample of the Medicare population. |
| CMS-NIH Emergency Department Subgroup |
Committee, Work group, Advisory group, or Task Force |
CMS |
NIDA |
With focused participation from both the Centers for Medicare and Medicaid Services (CMS) and experts across the National Institutes of Health (NIH), the CMS-NIH Emergency Department (ED) Subgroup is designed to accelerate collaboration between these two HHS Operating Divisions around issues involving SUD treatment initiation among people who present to the ED. |
| CMS-NIH Joint Leadership Council |
Committee, Work group, Advisory group, or Task Force |
CMS |
NCCIH, NCI, NHLBI, NIA, NIDA, NIDDK, NIMHD, NINR, OD/DPCPSI, OD/IMOD, OD/OER, OD/OSP |
Facilitates leadership-level development of mutual priorities between both Department of Health and Human Services (HHS) operating divisions. |
| CMS-NIH Joint Leadership Council Evidence Generation Working Group (EGWG) |
Committee, Work group, Advisory group, or Task Force |
CMS |
NCI, NIA, NIDDK, NIMH |
Organized in January 2018 for the purpose of developing a framework to enable the agencies to jointly address high-cost conditions; to consider the applicability of clinical trial results to Medicare, Medicaid, and Children’s Health Insurance Program beneficiaries; and to collaboratively identify evidentiary and policy issues of high mutual interest. |
| CMS-NIH Opioid Working Group Subgroup on Evidence for Nonpharmacological Treatments for Pain |
Committee, Work group, Advisory group, or Task Force |
CMS |
NCATS, NCCIH, NIAMS, NIDA, NINDS, NINR |
Discusses NIH/CMS partnerships in discussing nonpharmacological pain treatments and bridging research/policy gaps. |
| CMS-NIH Sickle Cell Disease Working Group |
Committee, Work group, Advisory group, or Task Force |
CMS |
NHGRI, NHLBI |
Working group that meets to explore what is required to implement CMS coverage for curative therapies in SCD. |
| Code Map Services for Interoperability of Common Data Models and Data Standards (CDMH III) |
Resource Development |
ASPE, FDA, ONC |
NCATS, NCI |
Code Map Services facilitate the use of open, consensus-based standards, consistent with HHS’s recognition of the need for greater interoperability of data and sharing of resources. The goal of this project is to facilitate Common Data Model (CDM) network interoperability, thereby expanding researchers’ access to clinical data that can be used for addressing new questions across a range of populations and settings. Specific objectives of the research include developing CDM interoperability services, improving quality and efficiency of model-to-model mappings, and extending the functionality of CDMs to allow submissions of clinical trials data. |
| Collaboration with the New York Lung Cancer Foundation |
Committee, Work group, Advisory group, or Task Force |
FDA |
NCI |
Dr. Peter Ujhazy has actively participated in the New York Lung Cancer Foundation Summit “Call to Action” on March 3-4, 2023 by co-chairing two sessions: 1. "Small cell lung cancer: Needs and future clinical trials" session, and 2. "What are we missing in lung cancer research?" session. The meeting lead to a white paper manuscript (see attached), which is now published. Peter Ujhazy contributed to the manuscript and is one of the co-authors. The paper addresses the most recent developments in lung cancer research and lists priorities and future opportunities in lung cancer clinical research. The manuscript is registered in the NIH MRS and Dr. Ujhazy's participation has been approved by DCTD leadership. The manuscript has the PMID39002176.In 2024 the same group met again in New York, NY on March 15-16. Dr. Ujhazy participated in the meeting too having similar responsibilities as in the 2023 meeting. While he contributed to the new white paper manuscript from this meeting, he is not listed as a co-author, rather than a contributor in the Acknowledgments because of the NCI restrictions on authorship. The paper was published in 2024 and has the PMID39413875. |
| Collaborative Community on Ophthalmic Imaging (CCOI) |
Committee, Work group, Advisory group, or Task Force |
FDA |
NEI |
CCOI held its fourth international meeting in January 2024 entitled “Expanding Datasets for Digitally Enhanced Management of Eye Diseases: Patient-Generated Data, Generative AI, 4D Imaging, and other Alternate Data Streams,” the meeting gathered experts from around the world and across academia, government institutions, patient groups, and the private sector to discuss the opportunities and challenges of utilizing various datasets in AI and ophthalmic imaging for the diagnosis and treatment of eye disease, with a special emphasis on issues of AI implementation in the real world. |